Assessing the risk of SARS-CoV-2 infection for pregnancy and as possible cause of birth defects
- Funded by FWO Belgium
- Total publications:0 publications
Grant number: G0H3120N
Grant search
Key facts
Disease
COVID-19start year
-99Known Financial Commitments (USD)
$268,140.6Funder
FWO BelgiumPrincipal Investigator
Hilde Van de Velde, Johan Neyts, Kai DallmeierResearch Location
BelgiumLead Research Institution
Katholieke Universiteit Leuven, Vrije Universiteit BrusselResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Since December 2019, SARS-CoV-2 causing COVID-19 spreads over the globe. Mortality rate is highest among the elderly while people at reproductive age usually experience mild or no symptoms. At current, data on SARS-CoV-2 infection during pregnancy are limited. Whereas infection during late trimester pregnancy seems to occur without adverse events, a recent study reported maternal and neonatal complications if the infection occurs in the early third trimester. Very little is known about maternal and neonatal outcomes after SARS-Cov-2 infection in the first and second trimester of pregnancy. Moreover, vertical transmission of SARS-CoV-2 during pregnancy is still a controversial issue. The aim of this project is to investigate (i) whether vertical transmission of SARS-CoV-2 occurs during embryogenesis, and (ii) if/how this causes damage to developing embryos. To that end, we will investigate the susceptibility of human oocytes and early embryos to SARS-CoV-2 infection and the possible impact on embryonic development in vitro. In addition we will study vertical transmission and consequences of maternal SARS-CoV-2 infection on embryogenesis in a hamster model in vivo. In the hamster model we will also estimate protection from vertical transmission by vaccination or passive serum transfer.